Background: First-line platinum-based therapy for advanced squamous cell carcinomas of the anal canal (SCCA) implies a risk of substantial side effects, and data on second-line treatment options are limited. Paclitaxel and Capecitabine are a well-known regimen with a moderate toxicity profile, but its efficacy has not been evaluated.
Methods: We conducted a retrospective study using Danish Hospital Registers of patients treated with Paclitaxel and Capecitabine for inoperable, recurrent, or advanced metastatic SCCA in Denmark, between January 2000 and July 2018.
Results: A total of 52 patients met the eligibility criteria. Median age was 60.7 years (range 42-83). Efficacy was observed, with an overall response rate in patients receiving first-line (N = 28) and second-line (N = 23) Paclitaxel and Capecitabine of 39.3% (2 with complete responses) and 17.4%, respectively. Median progression-free survival (PFS) was 4.5 months (95% CI 3.3-5.9) and 3.8 months (95% CI 2.4-5.5) with OS of 6.7 months (95% CI 5.9-8.5) and 5.9 months (95% CI 3.9-14), respectively. Performance status ≥2 and neutrophil to lymphocyte ratio ≥4 were significantly associated with a short PFS.
Conclusion: This study recognizes Paclitaxel and Capecitabine as a potential regimen for advanced SCCA, when recommended first-line therapy is not feasible or as a potential second-line treatment after failure of platinum-based chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124117 | PMC |
| http://dx.doi.org/10.1002/cam4.3886 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer.
Cancer Cell Int
December 2024
Department of Breast Surgery, The People's Hospital of Chuxiong Yi Autonomous Prefecture, No. 318 Lucheng South Road, Chuxiong, 675000, Yunnan, China.
Article Synopsis
- The study compared the efficacy and safety of two chemotherapy regimens—eribulin and utidelone combined with capecitabine—in patients with advanced breast cancer previously treated with anthracyclines and paclitaxel.
- It analyzed data from 85 patients over a five-year period, measuring endpoints such as progression-free survival (mPFS) and overall survival (mOS) using statistical methods like Kaplan‒Meier and Cox regression.
- Results showed that the utidelone/capecitabine group had longer mPFS (7.7 months) and mOS (22.0 months) compared to eribulin (5.2 months mPFS and 18.2 months mOS), indicating
Targeted and cytotoxic inhibitors used in the treatment of breast cancer.
Pharmacol Res
December 2024
Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791, United States. Electronic address:
Breast cancer is the most commonly diagnosed malignancy and the fifth leading cause of cancer deaths worldwide. Surgery and radiation therapy are localized therapies for early-stage and metastatic breast cancer. The management of breast cancer is determined in large part by the HER2 (human epidermal growth factor receptor 2), HR (hormone receptor), ER (estrogen receptor), and PR (progesterone receptor) status.
View Article and Find Full Text PDFPharmaceuticals in the environment: A strategy for prioritizing molecules of environmental concern.
Chemosphere
November 2024
Laboratory of Integrated Sciences, Universidade Federal de São Paulo, Diadema, SP, CEP 09972-270, Brazil; Department of Environmental Sciences, Laboratory of Ecology and Nature Conservancy (LECON), Group of Landscape Ecology and Conservation Planning (LEPLAN), Universidade Federal de São Paulo, Diadema, CEP 09972-270, Brazil; Antimicrobial Resistance Institute of São Paulo (ARIES), São Paulo, Brazil. Electronic address:
Article Synopsis
- * The proposed strategy focuses on antineoplastics with low biodegradability and significant ecological risks, utilizing data from São Paulo, Brazil, to predict the mass of these drugs entering waterways and creating a prioritization index based on multiple risk factors.
- * Key prioritized antineoplastics identified include Paclitaxel and Cisplatin, highlighting the strategy's versatility for adapting to different contexts and improving drug environmental impact assessments.
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
December 2024
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address:
Article Synopsis
- Paclitaxel plus ramucirumab is being evaluated as a second-line treatment for patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer, comparing it with continued oxaliplatin and fluoropyrimidine chemotherapy.
- The ARMANI trial involved 280 patients, who were randomly assigned to receive either the new treatment regimen or continue with their current chemotherapy for an additional 12 weeks.
- The primary goal of the study was to determine if the new treatment improved progression-free survival compared to the standard chemotherapy, with safety being closely monitored throughout the trial.
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis.
Lancet Oncol
December 2024
Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy; Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS Rome, Italy. Electronic address:
Background: In advanced pancreatic ductal adenocarcinoma (PDAC), first-line chemotherapy is the standard of care. Due to the absence of head-to-head comparisons in clinical trials, we performed this systematic review and network meta-analysis to compare treatment options for PDAC in terms of their efficacy and toxicity.
Methods: PubMed, the Cochrane Central Register of Controlled Trials, Embase, and oncological meetings websites were searched until Nov 15, 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!